Find News

Filter articles

Applied Filters

Showing 31 to 40 of 122 results

Eisai partners with Merck for cancer drug R&D

China, US09-03-2018

Japanese pharmaceutical company Eisai has teamed up with US-based Merck in a deal intended to strengthen the worldwide development and commercialisation of cancer drug Lenvima.

UK agrees £500m of life sciences deals in China

China, UK21-02-2018

More than £500 million worth of life sciences and healthcare agreements were signed between the UK and China during the UK Prime Minister’s visit to China earlier this month.

Allergan to buy Australian tissue repair company for $95m

Australia, Ireland12-02-2018

Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

AstraZeneca forms health tech partnerships in China


AstraZeneca has announced partnerships with Chinese companies Alibaba and Tencent, in agreements that will use emerging technologies to improve healthcare in China.

Abe & Partners makes two promotions


Japan-based Abe & Partners has promoted Michiko Kinoshita as partner and Tomohiro Kazama as counsel.

Tilleke & Gibbins promotes IP enforcement specialist


Southeast Asia-based law firm Tilleke & Gibbins has appointed an IP enforcement specialist to partner.

Aslan acquires global rights to cancer treatment


Singapore-based Aslan Pharmaceuticals has acquired the full global rights to develop, manufacture and commercialise a cancer treatment.

Pfizer and Basilea extend Cresemba licence agreement to Asia-Pacific


Basilea Pharmaceutica and Pfizer have reached a deal for a licence agreement for the antifungal medication Cresemba to cover China and 16 countries in the Asia-Pacific region.

Sanofi leads the way for gene therapy patents: report


CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.

AIPPI 2017: Eli Lilly counsel discusses ‘convoluted’ Amgen v Sanofi ruling


A patent counsel at Eli Lilly discussed a recent dispute pitting Amgen against Sanofi and Regeneron, saying an appeals court ruling was convoluted.

Showing 31 to 40 of 122 results